COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc. (CSCI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
csci · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for COSCIENS Biopharma Inc. (CSCI) measures how much investors pay for each dollar of the company's trailing earnings. CSCI's current PE ratio of N/A is calculated by dividing its stock price of $2.72 by its TTM earnings per share of -$0.73.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 9 fiscal years · Front-end computedMinQ1 · 25%7.3x
MedianQ3 · 75%55.0x
Max
At N/A, CSCI's current P/E is lower than in 0% of its annual fiscal year readings over the past 9 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
COSCIENS Biopharma Inc.You CSCI | $9M | N/A | — | -$0.73 |
 Apexigen, Inc. APGN | $10M | N/A | — | -$1.59 |
 Biora Therapeutics, Inc. BIOR | $1M | N/A | — | -$78.69 |
 Channel Therapeutics Corporation CHRO | $9M | N/A | — | -$2.30 |
 CervoMed Inc. CRVO | $27M | N/A | — | -$2.98 |
 IMV Inc. IMVIF | $0M | N/A | — | -$4.37 |
 Kineta, Inc. KA | $7M | N/A | — | -$1.42 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-5.93 | — | |
2023-12-31 FY2023 | — | $-1.89 | — | |
2022-12-31 FY2022 | 4.34x | $1.87 | -17.7% | |
2021-12-31 FY2021 | 5.27x | $1.44 | -45.3% | |
2020-12-31 FY2020 | 9.63x | $0.79 | — | |
2019-12-31 FY2019 | — | $-0.48 | — | |
2018-12-31 FY2018 | — | $-0.13 | — | |
2017-12-31 FY2017 | — | $-0.43 | — | |
2016-12-31 FY2016 | 4.78x | $1.69 | +40.1% | |
2015-12-31 FY2015 | 3.41x | $2.43 | -53.2% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for COSCIENS Biopharma Inc. (CSCI) measures how much investors pay for each dollar of the company's trailing earnings. CSCI's current PE ratio of N/A is calculated by dividing its stock price of $2.72 by its TTM earnings per share of -$0.73.
Frequently asked questions
CSCI pe ratio · 6 questionsCSCI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.72 and TTM EPS of -$0.73. Data sourced from Financial Modeling Prep via CSCI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · COSCIENS Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09